Dasatinib – Indications, and Side Effects
1. Introduction Dasatinib (brand name Sprycel) is a second-generation, reversible tyrosine kinase inhibitor (TKI) primarily used in the management of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its development was driven by the need for agents effective against imatinib-resistant CML, particularly in cases harboring BCR-ABL kinase domain…
